Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer. 1984

S G Allan, and A Gregor, and M A Cornbleet, and R C Leonard, and J F Smyth, and I W Grant, and G K Crompton

Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR 17%) were seen in patients with limited and extensive disease, respectively. Time to relapse was short in those responding (4-4.5 months), and most responders required additional treatments. The overall toxicity was minimal and patient compliance was high. This combination is useful for the palliative treatment of small cell lung cancer when aggressive chemotherapy is inappropriate.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010166 Palliative Care Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed) Palliative Treatment,Palliative Supportive Care,Palliative Surgery,Palliative Therapy,Surgery, Palliative,Therapy, Palliative,Care, Palliative,Palliative Treatments,Supportive Care, Palliative,Treatment, Palliative,Treatments, Palliative
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S G Allan, and A Gregor, and M A Cornbleet, and R C Leonard, and J F Smyth, and I W Grant, and G K Crompton
January 1982, Cancer chemotherapy and pharmacology,
S G Allan, and A Gregor, and M A Cornbleet, and R C Leonard, and J F Smyth, and I W Grant, and G K Crompton
January 1981, Cancer treatment reports,
S G Allan, and A Gregor, and M A Cornbleet, and R C Leonard, and J F Smyth, and I W Grant, and G K Crompton
September 1985, Japanese journal of cancer research : Gann,
S G Allan, and A Gregor, and M A Cornbleet, and R C Leonard, and J F Smyth, and I W Grant, and G K Crompton
January 1991, Respiration; international review of thoracic diseases,
S G Allan, and A Gregor, and M A Cornbleet, and R C Leonard, and J F Smyth, and I W Grant, and G K Crompton
February 1982, American journal of clinical oncology,
S G Allan, and A Gregor, and M A Cornbleet, and R C Leonard, and J F Smyth, and I W Grant, and G K Crompton
March 2008, Lung cancer (Amsterdam, Netherlands),
S G Allan, and A Gregor, and M A Cornbleet, and R C Leonard, and J F Smyth, and I W Grant, and G K Crompton
May 1987, European journal of cancer & clinical oncology,
S G Allan, and A Gregor, and M A Cornbleet, and R C Leonard, and J F Smyth, and I W Grant, and G K Crompton
February 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
S G Allan, and A Gregor, and M A Cornbleet, and R C Leonard, and J F Smyth, and I W Grant, and G K Crompton
February 1990, Tumori,
S G Allan, and A Gregor, and M A Cornbleet, and R C Leonard, and J F Smyth, and I W Grant, and G K Crompton
June 2003, Clinical oncology (Royal College of Radiologists (Great Britain)),
Copied contents to your clipboard!